Browsing by Author "Sousa, C."
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Effects of positive airway pressure therapy on neutrophil-lymphocyte ratio in males with obstructive sleep apneaPublication . Simão, C.; Sousa, C.; Pereira, M.; Feliciano, A.; Leitão, C.; Martinho, C.; Basto, R. Pinto; Pinto, P.; Bárbara, CristinaObstructive sleep apnea syndrome (OSAS) is associated with cardiovascular complications. The neutrophil-lymphocyte ratio (NLR) has been shown to be a marker of inflammation, being elevated in patients with cardiovascular disease. Several studies have demonstrated the protective effect of positive airway pressure regarding cardiovascular risk, however, there are few studies evaluating its effect on the reduction of NLR. The aim was to evaluate the effect of positive airway pressure (PAP) therapy on neutrophil-lymphocyte ratio after 6 months of PAP. This prospective study included 47 male patients. Patients with other sleep disorders, neuromuscular pathology, renal disease, thyroid pathology, heart failure, neoplasms, chronic inflammatory disease or prior PAP use were excluded. Basal NLR and after 6 months of PAP therapy (S9 Resmed®, Australia) were assessed.
- Grapevine responses to different irrigation techniques - growth, yield and fruit qualityPublication . Santos, T.P.; Sousa, C.; Conceição, N.; Amaral, P.; Lopes, C.M.; Rodrigues, M.L.; Maroco, J.P.; Pereira, J.S.; Chaves, M.M.
- Molecular analysis of medium-chain acyl-CoA dehydrogenase deficiency in PortugalPublication . Luz, A.; Violante, S.; Gaspar, A.; Lobo, Antunes M.; Rivera, I. A.; Silva, M. F. B.; Ramos, A.; Rocha, H.; Sousa, C.; Marcao, A.; Fonseca, H.; Ventura, F. V.; Leandro, P.; Vilarinho, L.; Tavares, de Almeida,
- Predictors of ACEI/ARB therapy in patients with hypertrophic cardiomyopathy : results of a national registryPublication . Martins, E.; Lebreiro, A.; Sousa, C.; Leite, S.; Sousa, A.; Belo, A.; Brito, Dulce; Cardim, N.Introduction: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are not considered disease-modifying drugs in hypertrophic cardiomyopathy (HCM) and their use is usually dependent on other clinical indications. Few data exist about the use of ACEI/ARB in HC in the real world, particularly in patients with intraventricular obstruction. Objective: In this study, we sought to determine the frequency of ACEI / ARB therapy in patients with HCM and the predictors for their use.